Genetic and transcriptional evolution alters cancer cell line drug responseUri Ben‐David, Todd R. Golub, Benjamin A. Siranosian et al.|Nature|2018Cited by 943
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Laura E. MacConaill, Katherine A. Janeway et al.|JCI Insight|2016Cited by 447
Cas9 activates the p53 pathway and selects for p53-inactivating mutationsOana M. Enache, Uri Ben‐David, Verónica Rendo et al.|Nature Genetics|2020Cited by 285
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y. Ng, Raphael Koch, Noriaki Yoshida et al.|Nature Communications|2018Cited by 114
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancerJennifer Y. Ge, Kornélia Polyák, Shaokun Shu et al.|Nature Communications|2020Cited by 97